Therapy Area

Regenxbio earns key FDA designation for DMD gene therapy

Regenxbio’s gene therapy RGX-202 gains an important regulatory marker as it looks to compete in a crowded field of DMD therapies.

Cardiovascular

View More

Central Nervous System

View More

Immunology

View More

Infectious Disease

View More

Oncology

View More

Respiratory

View More